Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Final ICH Q12 Post-Approval Changes Guideline Expected In November

Legal Impasse Likely To End, Established Conditions Sure To Be Clarified

Executive Summary

A final revision of the ICH Q12 lifecycle management guideline is expected to overcome a conflict with EU variations legislation and offer more clarity on what is, and what is not, an established condition subject to post-approval change reporting requirements.

You may also be interested in...



EMA Fee Revisions Expected To Resolve EC's Objections To ICH Q12 Guideline

Reducing dependence on Type II variation fees would free lifecycle management guideline from European Commission’s legal concerns.

Pharma Forges Ahead With ICH Q12 Preparations Despite Misgivings

While reservations are still being expressed on ICH Q12, the pharmaceutical industry is busily preparing for ICH Q12 implementation.

US FDA Trains Reviewers For Consistency On Post-Q12 Manufacturing Changes

Anticipating the eventual adoption of ICH Q12, the US FDA is training staff on some of its key principles. An agency official says ICH Q12 necessitates a new way of thinking about and reviewing regulatory submissions for post-approval changes and such training is necessary to ensure review consistency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS140524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel